Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preference of ELLIPTA vs HandiHaler in COPD
NCT02786927Phase 4Completed
- Sponsor
- GSK
- Start
- Jun 2016
- Primary completion
- Oct 2016
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial (4 arms), sponsored by GSK. Primary endpoint: Percentage of Participants Preferring the Inhaler Based on the Number of Steps Needed to Take the COPD Medication up to 18 days. Started Jun 2016; status: completed.
Beyond the preview
Go deeper on NCT02786927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02786927.